Use this url to cite publication: https://hdl.handle.net/20.500.12512/85282
CELSG CML 11 "ISTAHIT" Phase III Study - Planned Interim Analysis : High Doses Of Imatinib Mesylate (800MG
Type of publication
Konferencijų tezės nerecenzuojamame leidinyje / Conference theses in non-peer-reviewed publication (T2)
Author(s)
| Author | Affiliation |
|---|---|
Petzer, Andreas L | |
Title
CELSG CML 11 "ISTAHIT" Phase III Study - Planned Interim Analysis : High Doses Of Imatinib Mesylate (800MG
Day) Significantly Improve Rates of Major and Complete Cytogenetic Remissions (MCR, CCR) in Pretreated Ph+/BCR-ABL+ CML Patients in Chronic Phase / Andreas L. Petzer, Dominik Wolf, Dominic Fong, Thomas Lion, Irina Dyagil, Zvenyslava Masliak, Darinka Boskovic, Laimonas Griskevicius, Sandra Lejniece, Stefan Goranov, Liana Gercheva, Aleksandar Stojanovic, Dontcho Peytchev, Nikolay Tzvetkov, Rasa Griniute, Radka Oucheva, Hanno Ulmer, Merthin Kwakkelstein, Gianluca Fincato, Guenther Gastl
Date Issued
| Date |
|---|
2008-12-06 |
Extent
p. no. 6617.
Is part of
50th ASH Annual Meeting and Exposition : San Francisco December 6-9, 2008 : ASCO Annual Meeting Abstracts / American Society of Hematology. San Francisco, 2008.
Version
Originalus / Original
Series/Report no.
Journal of Clinical oncology, Volume 26, Issue 15S May 20, 2008
Type of document
type::text::conference output::conference proceedings::conference paper
Other Identifier(s)
(LSMU ALMA)990000712010107106
Coverage Spatial
Jungtinės Amerikos Valstijos / United States of America (US)
Language
Anglų / English (en)